|Day Low/High||38.44 / 40.66|
|52 Wk Low/High||24.21 / 59.25|
Yesterday I reestablished a long position in Canopy Growth - which has been on my Best Ideas List since early January, 2019. The shares are responding well to this news.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Apparently, this game is all about growth right now. It certainly is not about margins.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
I am back long Canopy Growth (very) small (I bought the opening). Moved up my buy entry price in light of a market that seems to be more accepting of speculative stocks.
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Assessing Aurora and its peers, strictly on the numbers.
In this day and age, companies must be 'disruptors' or get left in the dust.
Peltz's addition should pacify a persistent critique of the company.
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
Here are some of my individual buy levels of stocks that I want to add to or reestablish on weakness: * $157.50 * $1625 * $1150 * $42 * $55 * $46 * $46.50 * $182.50 * $31 * $40 * $23 * $65 * $16.75 * $35 * $27.75 * $60 * $95 * $48 * $87.50 Note: Lon...
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.
The plan is for Peltz to help the firm in maximizing potential markets to target.
In its first report on cannabis companies, Melius says prices are high.
And why I won't recommend any other stocks in these markets, right now.
A week ago, in 'Up In Smoke' on Feb. 19th, I soured on the short term price outlook for the pot stocks: Barron's cover story, "You've Got To Be High to Buy U.S. Marijuana Stocks," provides a cautionary outlook for pot stocks. I believe the space is...
If you are looking to invest in the fast-growing pot sector, this Canadian cannabis startup has been in early on the action.
Barron's cover story, "You've Got To Be High to Buy U.S. Marijuana Stocks," provides a cautionary outlook for pot stocks. I believe the space is extended and looks like it might be "rolling over" (awful pun!) technically. Canopy Growth is on my Best...
Right now they are speculative growth stocks through and through.
Rev Shark and I are in simpatico on: * The Bull Market In Complacency (which I discuss in my opener today) * A Possible Change in Market Complexion The former I am relatively certain of. The later will be contingent on a turn down in the absolute pe...
Let's check out the charts of four big names in the space.
While consolidation may be key to the cannabis market in 2019, this IPO is worthy of a deeper dive.
CBD could make coffee an around the clock craze.
Good action in and two stocks recently added to recently and initiated yesterday ( and ). , a victim of premature selling, is a total monster (+$3). (Still on my Best Idea List).
I am pleased with most of my moves over the last six weeks. Some of the better ones were the liquidation of Square and the sale of Amazon and Alphabet , practically at their highs. While I don't plan to buy back Square at lower prices, I most assur...